A better test for prostate cancer

Israeli founded Cleveland Diagnostics (CDX) is developing a technology and test kit that can eradicate inconclusive prostate-specific antigen (PSA) tests. CDX says it will save the $4000 cost per negative biopsy, currently necessary in 70% of current testing.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *